We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry Collaboration
News

Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry Collaboration

Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry Collaboration
News

Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under the terms of the agreement, scientists from the two companies are working together to advance one of Heptares’ internal high-value GPCR programmes.  Sygnature is providing synthetic chemistry services to produce a novel chemical library for Heptares to evaluate against purified, stabilised and functional proprietary GPCR targets (known as StaRs™, Stabilised Receptors).

Commenting on the agreement, Dr Simon Hirst, Sygnature’s Chief Executive Officer, said, “We are delighted that Heptares has chosen to collaborate with Sygnature on this programme.  Heptares’ decision to work with us demonstrates our growing reputation for delivering ‘top tier’ science coupled with high value and quality.  Over the past five years, Sygnature has established an excellent track record of success and enjoyed healthy growth because of its ability to deliver flexible scientific resource and drug discovery expertise, without high overhead costs.  We look forward to building a long-term scientific and business relationship with Heptares.”

Dr Miles Congreve, Head of Chemistry at Heptares said, "We are working with Sygnature on this drug discovery programme which forms a component of our efforts to develop novel GPCR-focused therapeutics.  Sygnature is becoming well-known and respected within the pharmaceutical industry for its high-quality medicinal and synthetic chemistry driven services.  Sygnature was therefore our choice as a trusted partner to leverage our own internal drug discovery capabilities.”

Advertisement